Cytek Biosciences (CTKB) Common Equity (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Common Equity data on file, last reported at $327.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 13.69% year-over-year to $327.6 million; the trailing twelve-month figure through Mar 2026 stood at $327.6 million (down 13.69% YoY), and the FY2025 full-year result was $341.7 million, down 13.64% from the prior year.
• Common Equity for Q1 2026 stood at $327.6 million, down from $341.7 million in the prior quarter.
• Across five years, Common Equity topped out at $425.5 million in Q4 2022 and bottomed at $327.6 million in Q1 2026.
• The 5-year median for Common Equity is $393.1 million (2023), against an average of $393.2 million.
• The widest annual swing landed in 2022, when Common Equity jumped 40644.2%; it then fell 13.69% in 2026.
• A 5-year view of Common Equity shows it stood at $425.5 million in 2022, then slipped by 7.63% to $393.1 million in 2023, then increased by 0.68% to $395.7 million in 2024, then declined by 13.64% to $341.7 million in 2025, then retreated by 4.12% to $327.6 million in 2026.
• The last three Common Equity figures came in at $327.6 million (Q1 2026), $341.7 million (Q4 2025), and $378.6 million (Q3 2025), per Business Quant data.

Peer Comparison